Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 8/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 7/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 7/20 | 1.00 |
| ▸ | CDK2 | P24941 | 7/20 | 1.00 |
| ▸ | CDK5 | Q00535 | 6/20 | 1.00 |
| ▸ | PDPK1 | O15530 | 6/20 | 1.00 |
| ▸ | CDK5R1 | Q15078 | 5/20 | 1.00 |
| ▸ | CCNA1 | P78396 | 3/20 | 1.00 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.67 |
| ▸ | GSK3B | P49841 | 4/20 | 0.67 |
| ▸ | CLK1 | P49759 | 2/20 | 0.67 |
| ▸ | CDC7 | O00311 | 1/20 | 0.67 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.67 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.67 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.67 |
| ▸ | PAK4 | O96013 | 1/20 | 0.67 |
| ▸ | PIM1 | P11309 | 1/20 | 0.67 |
| ▸ | PRKACA | P17612 | 1/20 | 0.67 |
| ▸ | GRK5 | P34947 | 1/20 | 0.67 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13008012 | 0.82 | CDK9 (0.69) | CDK9CCNT1CCNA2CDK2CDK5 | |
| SCHEMBL15721580 | 0.82 | DYRK1A (0.70) | CDK9CCNT1CCNA2CDK2CDK5 | |
| Meriolin 7 SCHEMBL1848789 | 0.81 | CCNT1 (0.84) | CDK9CCNT1CCNA2CDK2CDK5 | |
| SCHEMBL1043697 | 0.80 | CDK5 (1.00) | CDK9CCNT1CCNA2CDK2CDK5 | |
| SCHEMBL1603553 | 0.80 | DYRK1A (0.72) | CDK9CCNT1CCNA2CDK2CDK5 | |
| SCHEMBL29488162 | 0.80 | GSK3B (1.00) | CDK9CCNT1CCNA2CDK2CDK5 | |
| SCHEMBL573402 | 0.80 | GSK3B (1.00) | CDK9CCNT1CCNA2CDK2CDK5 | |
| SCHEMBL3781298 | 0.80 | CCNB2 (0.79) | CDK9CCNT1CCNA2CDK2CDK5 | |
| SCHEMBL18941997 | 0.80 | CCNT1 (1.00) | CDK9CCNT1CCNA2CDK2CDK5 | |
| SCHEMBL13239582 | 0.79 | CCNB2 (0.71) | CDK9CCNT1CCNA2CDK2CDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113816957-B | 4- (7-azaindole) -2-aminopyrimidine compounds and application thereof | 浙江工业大学 | 2023-04-07 | — | — | CN | claimed |
| CN-113816957-A | 4- (7-azaindole) -2-aminopyrimidine compounds and application thereof | 浙江工业大学 | 2021-12-21 | — | — | CN | claimed |
| JP-2011526931-A | — | — | 2011-10-20 | — | — | JP | claimed |
| US-20110201599-A1 | CDK Modulators | EXELIXIS, INC. (US) | 2011-08-18 | — | — | US | claimed |
| CN-102143746-A | CDK modulators | EXELIXIS INC | 2011-08-03 | — | — | CN | claimed |
| WO-2010003133-A2 | CDK MODULATORS | EXELIXIS INC. (US) | 2010-01-07 | — | — | WO | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| CN-118480029-A | 2-Aminopyrimidine compound or salt thereof, and preparation method and application thereof | 励缔(杭州)医药科技有限公司 | 2024-08-13 | — | — | CN | disclosed |
| CN-113816957-B | 4- (7-azaindole) -2-aminopyrimidine compounds and application thereof | 浙江工业大学 | 2023-04-07 | — | — | CN | disclosed |
| CN-113816957-B | 4- (7-azaindole) -2-aminopyrimidine compounds and application thereof | 浙江工业大学 | 2023-04-07 | — | — | CN | disclosed |
| CN-113816957-B | 4- (7-azaindole) -2-aminopyrimidine compounds and application thereof | 浙江工业大学 | 2023-04-07 | — | — | CN | disclosed |
| CN-113816957-A | 4- (7-azaindole) -2-aminopyrimidine compounds and application thereof | 浙江工业大学 | 2021-12-21 | — | — | CN | disclosed |
| US-20090176763-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
| US-20090176763-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
| US-7507826-B2 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-03-24 | — | — | US | disclosed |
| US-7507826-B2 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-03-24 | — | — | US | disclosed |
| WO-2008129152-A1 | PYRROLO[2,3-B]PYRIDINE COMPOUNDS, AZAINDOLE COMPOUNDS USED FOR SYNTHESIZING SAID PYRROLO[2,3-B]PYRIDINE COMPOUNDS, METHODS FOR THE PRODUCTION THEREOF, AND USES THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2008-10-30 | — | — | WO | disclosed |
| US-20070043063-A1 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2007-02-22 | — | — | US | disclosed |
| US-20070043063-A1 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176763-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | JAK3, JAK2, JAK1 | CDK9 85/4885CCNT1 878/4885CCNA2 506/4885 |
| US-20070043063-A1 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | LCK, PDXK, CHUK | CDK9 114/4885CCNT1 1640/4885CCNA2 2343/4885 |
| US-20110201599-A1 | CDK Modulators | CDK3, CDK1, CDKL1 | CDK9 6/4885CCNT1 25/4885CCNA2 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.